WHO Sounds Alert Over Critical Lack of Weight-Loss Injections
Fewer than one in 10 patients eligible to benefit from weight-loss injections including Wegovy have access to them, caution the global health agency as it publishes its first recommendations on the therapies.
Given over a billion people worldwide currently obese, it is advocating for more widespread and fairer availability to this class of drugs.
According to projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidelines recognises that excess weight is a long-term condition that can be addressed with comprehensive and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant obstacles to widespread availability to the treatments that can aid individuals in losing considerable body mass, says the organization.
GLP-1 Therapy Supply Crisis
Even in the current best projected outlook, the production of these medications would only suffice for approximately 100 million people – under 10% of those who need them, per the WHO.
The advice encourages countries and companies to increase availability, by approaches like patent sharing.
Exclusive production rights on semaglutide – the core component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
How Obesity Injections Operate
GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and increase satiety so people consume fewer calories.
Patients usually start to lose weight in the initial weeks of commencing the once-weekly jabs.
Research points to users may see weight return after a year of stopping the medication, because their normal food cravings come back.
To be overweight or obese elevates your likelihood for contracting medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects individuals in every country and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
